News Snapshot:
BEIJING -- A COVID-19 vaccine candidate developed by the Institute of Microbiology under the Chinese Academy of Sciences has shown to be safe in early-stage trials, suggesting potential for further clinical tests. The results of phase-1 and phase-2 trials support the safety and immunogenicity of this recombinant subunit vaccine in healthy participants, and no serious adverse events have been found so far, the institute said in a statement on Friday. Jointly developed by the institute and Chongqing Zhifei Biological Products Co Ltd, the vaccine was issued with a clinical research permit from the National Medical Products Administration on June 19....
